


PHARMACEUTICAL 2020

## AKORN INC Rank 113 of 362







PHARMACEUTICAL 2020

AKORN INC Rank 113 of 362

The relative strengths and weaknesses of AKORN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AKORN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 223% points. The greatest weakness of AKORN INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 246% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	480,047
Cost of Goods Sold	429,723
Intangible Assets	483,724
Liabilities, Current	985,587
Liabilities, Non-Current	68,760
Other Assets	29,335
Other Compr. Net Income	-3,772
Other Expenses	99,942
Other Liabilities	0
Other Net Income	-68,163
Property and Equipment	295,533
Research and Development	37,500
Revenues	682,429
Selling, General and Administrative Expense	273,871

Output Variable	Value in 1000 USD
Assets	1,288,639
Liabilities	1,054,347
Expenses	841,036
Stockholders Equity	234,292
Net Income	-226,770
Comprehensive Net Income	-228,656
Economic Capital Ratio	-57%

